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Microarray
Whole exome sequencingCopy number variation (CNV) is a common source of genetic variation that has been implicated inmany genomic
disorders, Mendelian diseases, and common/complex traits. Genomic microarrays are often employed for CNV
detection. More recently, whole-exome sequencing (WES) has enabled detection of clinically relevant point
mutations and small insertion—deletion exome wide. We evaluated (de Ligt et al. 2013) [1] the utility of short-
read WES (SOLiD 5500xl) to detect clinically relevant CNVs in DNA from 10 patients with intellectual disability
and compared these results to data from three independent high-resolution microarray platforms. Calls made
by the different platforms and detection software are available at dbVar under nstd84.
© 2014 The Author. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).SpeciﬁcationsOrganism/cell line/tissue Human blood
Sex –
Sequencer or array type Affymetrix 250 k, Affymetrix CytoScanHD, N
imblegen Custom ExonArray, Solid 5500xl
Data format Analyzed
Experimental factors Normal
Experimental features Positive samples with rare de-novo coding CNV
Consent All patients gave their written informed
consent before study entry.
Sample source location NADirect link to deposited data
http://www.ncbi.nlm.nih.gov/dbvar/studies/nstd84/ (CNV calls
from all platforms/programs)
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE46060
(raw 250 k data). Hehir-Kwa).
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Sample selection
Ten samples were selected that had previously been diagnostically
reported as containing at least one clinically relevant, rare de novo
CNV associated with intellectual disability (ID), detected by routine
microarray based screening within the Department of Human Genetics,
Radboud University Medical Centre, Nijmegen [1]. These CNVs were
chosen to represent a wide range of clinically relevant CNVs detected
by microarray based analysis in our Genome Diagnostics division. The
selected CNVs (1) contained at least one coding region, (2) were
validated de novo using the same microarray platform on parental
DNAs, (3) occurred across a variety of chromosomes, (4) ranged in
copy number state from zero to three, and (5) ranged in genomic size
from 15 kb to 24 Mb (Table 1).
Eleven of these de novo CNVs were detected using an Affymetrix
250K NspI (Affymetrix, Santa Clara, CA) microarray and one, in patient
1, with the Affymetrix 2.7M microarray platform (Table 1).
Whole exome sequencing
Genomic DNA from these 10 samples was isolated from blood using
the QIAamp DNA Mini Kit (Qiagen, Venlo, The Netherlands). Whole
exome sequencing (WES) was performed at the University Medicalhe CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Table 1
Overview of the detection of 12 clinically relevant de novo CNVs.
Discovery microarray WES read depth algorithms
Patient Chromosome Estimated start
position (kb)
Estimated end
position (kb)
CNV size (kb) Copy number
state
Nr. Genes CONTRA cn.MOPS ExonDepth CoNIFER
1 chr10 89,642.6 89,657.5 14.9 1 1a – – – –
2 chr19 33,371.1 33,394.2 23.0 0 1 – – V V
3 chr8 77,745.6 77,795.2 49.6 1 1 – - V V
4 chr17 1,203.6 1,516.5 312.9 3 8 - – V V
5 chr16 29,673.2 29,988.3 315.1 1 16 – – V V
6 chr15 43,759.8 44,862.9 1103.2 1 24 – – – V
7 chr2 233,166.3 233,886.7 720.5 3 16 – – V V
8 chrX 6495.3 7951.7 1456.4 0 5 – – V V
9 chr2 239,952.7 241,373.1 1420.5 3 14 – – V V
chr2 241,442.7 243,001.9 1559.2 1 31 – – V V
chr15 60,489.7 62,906.5 24,603.6 3 210 – – V V
10 chr20 77,771.0 102,374.6 2416.8 3 91 – V V V
CNVs as detected by the discoverymicroarray (hg19), genomic location, size, predicted copynumber state and the number of genes in the region. a. A single exondeletion.Detection by the
different WES approaches; –, CNV is not detected with a minimum overlap of 30%, and V, detected with a minimum overlap of 30%.
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The samples were enriched using the Agilent SureSelect V2 protocol,
and sequencing was performed on a SOLiD 5500xl system (Life Tech-
nologies) to a median read depth of 67 across targeted regions. Read
correction and mapping were performed with Lifescope v1.3 (Life
Technologies), using default settings. After mapping reads with a map-
ping quality (MAPQ) value below 20 were discarded to select reliably
mapped reads. The value of 20 was based on read depth ratio of the X
chromosome between female and male samples. This was the lowest
quality value that resulted in a 0.5 ratio.
The WES data were analyzed with four different published CNV
detection programs; (1) cn.MOPS v1.6.4 [2], (2) CONTRA v2.0.3 [4],
(3) CoNIFER v0.2.0 [3], and (4) ExomeDepth v0.8.4 [6], with hg19-
based RefSeq gene exon deﬁnitions as target regions in the analysis.
Overlapping exonic regions were merged resulting in a list with
unique genomic regions for further analysis. The tools were selected
based on their availability and ability to perform rare CNV detection
on .bam ﬁles.
CNV segments identiﬁed by WES underwent additional merging.
CNV calls of the same copy number were merged if they were within
5 Mb distance and fewer than 30 informative data points were
between the calls. These values protect against overcalling while
allowing for gene deserts, resulting in a more robust and uniform
call-set.Affymetrix 250K NspI & Affymetrix 2.7M microarray
Samples were processed in accordance with the manufacturer's
instructions. Hybridization, washing and scanning were performed
with appropriate Affymetrix GeneChip products. The 250K microarrays
image processing was performed with Affymetrix GeneChip Command
Console software. Genotypes were called with Affymetrix Genotyping
Console Software v2.1 using the BRLMM algorithm with default-
calling threshold of 0.5 and a prior size of 10,000 bases. Samples were
required to have a minimum Quality Control SNP call rate of 90%. CNV
identiﬁcation was performed using CNAG v2.0 with default HMM
settings [5]. Image processing, CNV calling and merging for the 2.7M
microarray was performed via Affymetrix Power Tools v1.14.3 with
default settings and calling thresholds. Data viewing and analysis was
performed with the Affymetrix Chromosome Analysis Suite (ChAS)
software v2.0 and the UCSC genome browser (UCSC Genome Browser
on Human Feb. 2009, GRCh37/hg19, NCBI Build 37.3). Samples were
required to have minimum quality thresholds of; MAPD ≤ 0.2049,
SNP-QC N 1,1 and WavinessSegCount ≤ 10.Affymetrix CytoScanHD (2.6M) microarray
The Affymetrix CytoScanHD platformwith 2.6 million probes was
used to serve as a benchmark of the high resolution microarrays cur-
rently used in a diagnostic setting at the UMCN genetics department.
Experiments were performed in the UMCN according to the
manufacturer's speciﬁcations. CNVs were called with Affymetrix
Power Tools v1.14.3 using default settings and calling thresholds.
Data viewing and analysis was performed with ChAS v2.0 and the
UCSC genome browser (UCSC Genome Browser on Human Feb.
2009, GRCh37/hg19, NCBI Build 37.3). Samples were required to
have minimum quality thresholds of; MAPD b 0.25, SNPQC N 15
and Waviness-SD b 0.12.NimbleGen custom design ExonArray (4.2 M) microarray
A custom, comparative genomic hybridization (CGH) array with ap-
proximately 4.2 million oligonucleotide probes was manufactured for
BCM by Roche NimbleGen (RNG); this array, referred to as the
“ExonArray”, served as an orthologonal independent experimental ap-
proach and a high resolution benchmark for CNV detection. The custom
array design included 2.15 million backbone probes and 1.85 million
supplemental exonic probes targeted to the RNG “Big Exome” (exome
deﬁnition includes all exons from RNG Exome v2.0, Agilent SureSelect
50Mb, RefSeq, CCDS, and the BCM Human Genome Sequencing Center
HGSC content (both VCRome and HGSCv1 designs)). The aim of the de-
sign was to cover each exon (and ﬂanking sequence, if necessary) with
at least 8 probes. A series of test arrays was manufactured with 10X
oversampling of exon-targeted probes (i.e. 80 per exon) and runs
with control DNA to empirically identify the 8 probes per exon with
best linear signal response to a range of DNA concentrations, which
were included in the ﬁnal ExonArray design. In the ExonArray, the
ideal coverage of 8 or more probes was achieved for N135,000 (~86%)
of the targeted exons; 249 (0.16%) of the exons could not be targeted
at all.
The 10 patient samples were analyzed with the ExonArray at BCM
according to the manufacturer's speciﬁcations and using gender
matched control DNA (HapMap individuals NA10851 and NA15510).
Segmentation was performed with RNG DEVA software, using default
settings (requiring a minimum of ﬁve probes per segment), to account
for the high resolution of the platform the maximum number of seg-
ments allowed per chromosome was increased to 500. CNVs were de-
rived from the segments using a log2 deviation value of ≤ −0.415
(the theoretical log2 of a 50% mosaic heterozygous loss) for deletions
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gain) for duplications and higher order gains.
Segments were merged when they were; 1) within 1 Mb of each
other, 2) fewer than 100 probes were located between the events and
3) the average log2 values had a maximum difference of 0.5.
Evaluating the CNV detection power of WES
The false negative (FN) detection rate of WES was calculated by
measuring the number of CNV events detected using the high-
resolution microarray platforms that were missed by WES. To pre-
vent overestimation due to platform design (exon targeted vs.
whole genome), we accounted for both the exome enrichment tar-
gets and the detection power of WES. We selected CNVs that were
identiﬁed by at least two independent microarray platforms (mini-
mum overlap of 30% of the CNV region, to allow for breakpoint in-
accuracies due to the large differences in probe densities) and the
CNV had to encompass at least three exons.
For each CNV, the largest region, detected by the CytoScanHD or the
ExonArray, was used for further analysis. After applying these selection
criteria to the total set of 6074 CNVs identiﬁed by the different micro-
array experiments, the resulting consensus dataset contained 97 CNVs.
Of these 97 consensus CNVs, 25 did not occur in the common CNV
dataset and were considered rare CNVs. Consensus CNVs were only
considered as positively detected by WES if a CNV was called in the
same region and overlapped the consensus CNV region for at least 30%.
Discussion
We present a high quality data set of CNVs in 10 individuals. The
use of different techniques and algorithms allowed a systematicassessment of detection power and accuracy. The high-resolution
array datasets could be studied in more detail for their discrepancies
or the mechanisms of genomic instability leading to small (coding)
events. The WES callset is useful for developers of calling software
to identify the caveats and advantages of the different models evalu-
ated in our study.Conﬂict of interest
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